Discontinuation report EVUSHELD
| Report ID | 224094 |
| Drug Identification Number | 02526271 |
| Brand name | EVUSHELD |
| Common or Proper name | CILGAVIMAB TIXAGEVIMAB SOLUTION |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | DORMANT |
| Active Ingredient(s) | |
| Strength(s) | 150MG 150MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Packaging size | 2 single dose vials |
| ATC code | J06BD |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2024-03-27 |
| Remaining supply date | 2023-01-09 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: medinfo.canada@astrazeneca.com. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2024-04-04 | French | Compare |
| v5 | 2024-04-04 | English | Compare |
| v4 | 2024-04-02 | French | Compare |
| v3 | 2024-04-02 | English | Compare |
| v2 | 2024-04-02 | French | Compare |
| v1 | 2024-04-02 | English | Compare |
Showing 1 to 6 of 6